PrimeGenX Therapeutics

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Fineline Cube Feb 3, 2026

PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immuno‑inflammation biotech founded in 2016, made an initial public...

Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Fineline Cube Feb 3, 2026

Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive...

Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Company

GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength

Company

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

Others

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength